S1PR Modulator Therapy for Late-Stage Alzheimer’s Synaptic Deficits

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective treatment for Alzheimer's dementia, particularly in its late stages, and existing treatments do not halt or reverse the progression of synaptic deficits and memory dysfunction.

Innovation Solution

The use of sphingosine-1-phosphate receptor (S1PR) modulators, such as fingolimod, siponimod, ozanimod, ceralifimod, GSK2018682, ponesimod, and amiselimod, either alone or in combination with other therapeutic substances, to treat Alzheimer's dementia.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for Alzheimer's dementia, then current standard of care is maintained, but synaptic deficits and memory dysfunction continue to progress

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidpreservation of cognitive function

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the pharmacological parameter by introducing S1PR modulators (fingolimod, siponimod, ozanimod, ceralifimod, ponesimod, amiselimod) that target sphingosine-1-phosphate receptors, fundamentally altering the mechanism of action from conventional cholinesterase inhibitors or NMDA receptor antagonists to immunomodulatory agents that can halt and reverse synaptic deficits

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful inflammatory response mediated by microglia and astroglia into a beneficial therapeutic opportunity by using S1PR modulators to regulate immune cell migration and reduce neuroinflammation, thereby protecting neurons and restoring synaptic function

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If S1PR modulators are used to treat Alzheimer's dementia, then progression of synaptic deficits can be stopped and potentially reversed, but this represents a departure from conventional treatment approaches

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcomplexity of treatment mechanism

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The S1PR modulators exhibit multi-functionality by simultaneously acting on multiple pathways: regulating T-cell migration, modulating microglia activation, protecting neurons from apoptosis, and enhancing synaptic plasticity, thereby achieving broad therapeutic effects against Alzheimer's pathology through a single molecular target

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

S1PR modulators can stop the progression and potentially reverse synaptic deficits and memory dysfunction in Alzheimer's dementia, offering a therapeutic benefit even in late-stage disease.

Implementation Method 1

The sphingosine-1-phosphate receptors are a family of seven helix transmembrane G protein-coupled receivers that recognize and bind extracellular sphingosine-1-phosphate to affect cellular processes

Methodology Applied

Scientific EffectReceptor binding and modulation:

Data Source

PatentUS20250325501A1A sphingosine-1-phosphate receptor (s1PR) modulator for use in treating a patient suffering from alzheimer's dementia

Publication Date: 2025.10.23 OTTO VON GUERICKE UNIV MAGDEBURG

AI summary

The present invention relates to a sphingosine-1-phosphate receptor (S1PR) modulator for use in treating a patient suffering from Alzheimer's dementia.